胰高血糖素样肽-1激动剂利拉鲁肽作为肥胖症的药物治疗方法。
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.
作者信息
Crane James, McGowan Barbara
机构信息
Guy's and St Thomas' NHS Foundation Trust - Diabetes and Endocrinology, St Thomas' Hospital Westminster Bridge Road, London SE1 7EH, UK.
Guy's and St Thomas' NHS Foundation Trust - Diabetes and Endocrinology, and King's College London - Diabetes and Nutritional Sciences, London, UK.
出版信息
Ther Adv Chronic Dis. 2016 Mar;7(2):92-107. doi: 10.1177/2040622315620180. Epub 2015 Dec 16.
Abstract
There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.
摘要
全球肥胖问题盛行，这将持续给世界各地的医疗系统带来经济负担。通过饮食和锻炼来解决肥胖问题应始终是首要干预措施，但事实证明，这对大量患者并不有效。药物治疗选择有限，许多以前可用的药物因安全问题已被撤出市场。目前，只有减肥手术能够实现显著且持久的体重减轻。本文简要回顾了肥胖药物治疗的历史，然后重点关注使用GLP-1激动剂利拉鲁肽作为减肥药物的临床试验证据，并将其疗效与其他新兴的肥胖症药物疗法进行比较。
相似文献
1
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.胰高血糖素样肽-1激动剂利拉鲁肽作为肥胖症的药物治疗方法。
Ther Adv Chronic Dis. 2016 Mar;7(2):92-107. doi: 10.1177/2040622315620180. Epub 2015 Dec 16.
2
Liraglutide in the treatment of obesity.利拉鲁肽治疗肥胖症
Expert Opin Biol Ther. 2014 Aug;14(8):1215-24. doi: 10.1517/14712598.2014.925870. Epub 2014 Jun 6.
3
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.肥胖症药物的获益-风险评估：重点关注胰高血糖素样肽-1 受体激动剂。
Drug Saf. 2019 Aug;42(8):957-971. doi: 10.1007/s40264-019-00812-7.
4
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.利拉鲁肽治疗肥胖的疗效和安全性评估。
Expert Opin Pharmacother. 2020 Feb;21(3):275-285. doi: 10.1080/14656566.2019.1695779. Epub 2019 Dec 2.
5
The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.当前世界肥胖问题的负担以及可用的新治疗方法：聚焦于3.0毫克利拉鲁肽
Diabetol Metab Syndr. 2017 May 31;9:44. doi: 10.1186/s13098-017-0242-0. eCollection 2017.
6
GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.GDF15 与利拉鲁肽协同作用，但不是减肥手术诱导小鼠体重减轻所必需的。
Mol Metab. 2019 Mar;21:13-21. doi: 10.1016/j.molmet.2019.01.003. Epub 2019 Jan 14.
7
Current and emerging pharmacotherapies for obesity in Australia.澳大利亚当前和新兴的肥胖症药物治疗方法。
Obes Res Clin Pract. 2017 Sep-Oct;11(5):501-521. doi: 10.1016/j.orcp.2017.07.002. Epub 2017 Aug 14.
8
Pharmacotherapy for the management of obesity.肥胖管理的药物治疗。
Metabolism. 2015 Nov;64(11):1376-85. doi: 10.1016/j.metabol.2015.08.001. Epub 2015 Aug 12.
9
[Recent progress and novel perspectives on obesity pharmacotherapy].[肥胖症药物治疗的最新进展与新观点]
Arq Bras Endocrinol Metabol. 2010 Aug;54(6):516-29. doi: 10.1590/s0004-27302010000600003.
10
Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.利拉鲁肽：一种用于慢性体重管理的胰高血糖素样肽-1激动剂。
Consult Pharm. 2016 Dec 1;31(12):685-697. doi: 10.4140/TCP.n.2016.685.
引用本文的文献
1
Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.使用GLP-1受体激动剂治疗的2型糖尿病患者青光眼的发病率：一项系统评价和荟萃分析。
Endocrinol Diabetes Metab. 2025 Jul;8(4):e70059. doi: 10.1002/edm2.70059.
2
A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.已批准的胰高血糖素样肽-1（GLP-1）受体激动剂和双GLP-1/葡萄糖依赖性促胰岛素多肽（GIP）受体激动剂的药代动力学及药物相互作用综述
Drug Des Devel Ther. 2025 Apr 30;19:3509-3537. doi: 10.2147/DDDT.S506957. eCollection 2025.
3
Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.利拉鲁肽治疗可改善重度肥胖青少年的血糖调节异常、身体成分、心脏代谢指标及失控的饮食行为。
J Clin Res Pediatr Endocrinol. 2025 Mar 19;17(1):68-75. doi: 10.4274/jcrpe.galenos.2024.2023-10-10. Epub 2024 Sep 23.
4
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.靶向 GLP-1 受体以减少尼古丁使用障碍：临床前和临床证据。
Physiol Behav. 2024 Jul 1;281:114565. doi: 10.1016/j.physbeh.2024.114565. Epub 2024 Apr 23.
5
Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.抗肥胖药物治疗的进展：当前治疗方法、新兴疗法及挑战
Cureus. 2023 Oct 7;15(10):e46623. doi: 10.7759/cureus.46623. eCollection 2023 Oct.
6
Sex Differences in the Preventive Effect of Cardiovascular and Metabolic Therapeutics on Dementia.心血管和代谢疗法对痴呆症预防作用的性别差异
Biomol Ther (Seoul). 2023 Nov 1;31(6):583-598. doi: 10.4062/biomolther.2023.115.
7
Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes.人源分选连接蛋白可变剪接受胰高血糖素样肽-1(GLP1)调控在脂肪细胞中的作用。
Int J Mol Sci. 2023 Sep 20;24(18):14324. doi: 10.3390/ijms241814324.
8
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.关于抗糖尿病药物相关体重减轻的综合综述
Life (Basel). 2023 Apr 14;13(4):1012. doi: 10.3390/life13041012.
9
Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool.肥胖症药物：临床研究评价与推荐分级、评估、制定和评价工具。
Nutrients. 2023 Jan 24;15(3):606. doi: 10.3390/nu15030606.
10
Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.利拉鲁肽通过 AMPK 和焦亡相关 NLRP3 通路减轻中枢神经系统炎症和脱髓鞘。
CNS Neurosci Ther. 2022 Mar;28(3):422-434. doi: 10.1111/cns.13791. Epub 2022 Jan 5.
本文引用的文献
1
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.利拉鲁肽 3.0 毫克在体重管理中的随机、对照试验。
N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.
2
Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials.有意减肥与全因死亡率：随机临床试验的荟萃分析
PLoS One. 2015 Mar 20;10(3):e0121993. doi: 10.1371/journal.pone.0121993. eCollection 2015.
3
GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study.在糖尿病前期、筛查发现的2型糖尿病和肥胖症患者中，胰高血糖素样肽-1（GLP-1）对口服葡萄糖的反应降低，且受性别影响：ADDITION-PRO研究
Diabetes. 2015 Jul;64(7):2513-25. doi: 10.2337/db14-1751. Epub 2015 Feb 12.
4
How safe is metabolic/diabetes surgery?代谢/糖尿病手术有多安全？
Diabetes Obes Metab. 2015 Feb;17(2):198-201. doi: 10.1111/dom.12405. Epub 2014 Nov 19.
5
Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.使用胰高血糖素样肽-1（GLP-1）受体激动剂进行治疗可减少体重减轻维持期间游离血浆瘦素的下降。
Int J Obes (Lond). 2015 May;39(5):834-41. doi: 10.1038/ijo.2014.177. Epub 2014 Oct 7.
6
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.弓状核介导胰高血糖素样肽-1受体激动剂利拉鲁肽依赖性体重减轻。
J Clin Invest. 2014 Oct;124(10):4473-88. doi: 10.1172/JCI75276. Epub 2014 Sep 9.
7
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.利用真实世界数据评估基于肠促胰岛素的治疗与急性胰腺炎风险的关联：来自观察性研究的 1,324,515 例患者的荟萃分析。
Diabetes Obes Metab. 2015 Jan;17(1):32-41. doi: 10.1111/dom.12386. Epub 2014 Oct 6.
8
Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.基于肠促胰岛素的治疗方法与急性胰腺炎风险：一项观察性研究的系统评价和荟萃分析
Endocrine. 2015 Mar;48(2):461-71. doi: 10.1007/s12020-014-0386-8. Epub 2014 Aug 22.
9
10
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.胰高血糖素样肽 1 对食欲和体重的影响：重点关注中枢神经系统。
J Endocrinol. 2014 Mar 7;221(1):T1-16. doi: 10.1530/JOE-13-0414. Print 2014 Apr.
Zotero 插件